Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 13144Neoplasms 10492Carcinoma, Non-Small-Cell Lung 6878Prostatic Neoplasms 6276Colorectal Neoplasms 5950Lung Neoplasms 5110Multiple Myeloma 3579Pancreatic Neoplasms 3564Leukemia, Myeloid, Acute 3512Neoplasm Metastasis 3511Carcinoma, Hepatocellular 3277Ovarian Neoplasms 3173Melanoma 3142Stomach Neoplasms 3058Lymphoma 2984Head and Neck Neoplasms 2608Recurrence 2557Precursor Cell Lymphoblastic Leukemia-Lymphoma 2500Leukemia 2362Colonic Neoplasms 2328Brain Neoplasms 2317Lymphoma, Non-Hodgkin 2269Uterine Cervical Neoplasms 2193Rectal Neoplasms 2192Glioblastoma 2018Leukemia, Lymphocytic, Chronic, B-Cell 1992Carcinoma, Renal Cell 1915Squamous Cell Carcinoma of Head and Neck 1880Lymphoma, Follicular 1851Esophageal Neoplasms 1801

Interventions

ribociclib 1LSZ102 1Alpelisib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Advanced or Metastatic ER+ Breast Cancer × Clear all
NCT02734615 2022-08-01

Phase I/Ib Trial of LSZ102 Single Agent or LSZ102 + LEE011 or LSZ102 + BYL719 in ER+ Breast Cancers

Novartis

Phase 1 Terminated
199 enrolled
Breast

Advanced or Metastatic ER+ Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡